Talecris-Sponsored Scientific Symposium Examines Advances in Use of Intravenous Immune Globulin for Neurological Disorders

Special Session Held at European Federation of Neurological Societies Congress

A scientific symposium which featured the latest information on
potential therapeutic applications of intravenous immune globulin
(IVIG) in neurological disorders was presented yesterday at the 11th
Congress of the European Federation of Neurological Societies in
Brussels, Belgium. The program, entitled "Advances in the Use of IVIG
in Neurological Disorders," was sponsored by Talecris Biotherapeutics,
Inc. (http://www.talecris.com). The program featured presentations and
discussions of the growing evidence supporting use of IVIG to treat a
variety of neurological disorders including autoimmune neuropathies
and other autoimmune neurological disorders.

The program, chaired by Dr. Hans-Peter Hartung, Department of
Neurology, Heinrich-Heine University, Dusseldorf, Germany, included
experts in neurology and IVIG therapy who presented the latest
scientific and clinical data. Presentations focused on the mechanisms
of action of IVIG in neurological disorders, evidence supporting the
use of IVIG for autoimmune neuropathies including chronic inflammatory
demyelinating polyneuropathy (CIDP), and the current status and future
prospects of IVIG in other autoimmune disorders of the
neurological system.

"This program provided an excellent overview of what scientists
and medical professionals have learned about immune-based
pathophysiological mechanisms for neurological disorders, and how IVIG
might provide new approaches to treatment," said Dr. Hartung. "We
thank Talecris for their support of this important program and their
commitment to advancing scientific knowledge surrounding potential
neurological uses of IVIG."

About Talecris Biotherapeutics: Inspiration. Dedication.
Innovation.

Talecris Biotherapeutics is a global biotherapeutic and
biotechnology company that discovers, develops and produces critical
care treatments for people with life-threatening disorders in a
variety of therapeutic areas including immunology, pulmonology, and
hemostasis. Talecris is proudly building upon a 60-year legacy of
innovation and a commitment to improving the lives of people who rely
on its therapeutic products. With an emphasis on scientific inquiry
and technological excellence, Talecris is expanding its current
portfolio of products, programs, and services through its own
world-class product development organization as well as through
strategic initiatives that leverage its strengths with those of its
partners.

Talecris, which earned revenues exceeding $1.1 billion in 2006, is
headquartered in biotech hub Research Triangle Park, N.C., and employs
more than 3,000 talented people worldwide.

To learn more about Talecris and how our employees are making a
difference in the lives of patients and the healthcare community,
visit www.talecris.com.